Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How one man's concern saved his brothers from heart disease - 2Danish warship sunk by famed British admiral discovered after 225 years
- 3Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- 4Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- 5Toyota Motor Europe to roll out smart EV charging through new partnerships
- Teen drug use remains low, but survey finds small rise in heroin and cocaine use
- How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- The Ascent of the Kona SUV: How Hyundai's Reduced Hybrid Is Vanquishing the Streets
- How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child
- Web designers for Independent ventures
- 'Senseless violence' erupts at Christmas tree lighting; 4 injured
- EU chief urges Iran to free imprisoned protesters, lift internet ban
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
